To allow for easier identification of MHO, a subset of obese individuals at lower risk of CVD death and all-cause mortality, investigators used data from 2 large patient cohorts to craft a definition of MHO based on common risk factors.
This study that examined whether this type of strength training would improve blood pressure, endothelial function, and arterial stiffness in older patients with elevated systolic BP.
Findings from a prospective cohort study indicate that reducing work hours—from 55 or more a week to between 35 and 40—may be a preventive strategy for patients with a history of heart attack.
A meta-analysis demonstrated a positive and substantially linear relationship between sodium exposure and blood pressure, even at sodium intake levels lower than current public health recommendations.
Cholesterol guidelines recommend at least a moderate-intensity statin in older adults with ASCVD. But that’s not happening consistently in clinical practice.
Data from the Swedish MI registry showed an increased risk of all-cause mortality in this group of patients, suggesting a need to re-examine use of evidence-based pharmacotherapy.
Validated family history is a key risk factor for ASCVD and may be the largest contributor to risk. An accurate family history of ASCVD can help determine the need for measuring CAC--and ultimately the need for lipid-lowering therapy.
A recent study explores whether coronary artery calcium levels can help identify patients most likely to experience a net benefit from aspirin therapy for ASCVD.
These data provide evidence that increased levels of NT-proBNP in patients without cardiovascular disease are associated with increased risk for cardiovascular events.